BT-114143 clinical trials
How each study uses BT-114143 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the BT-114143 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- BT-114143
- 1
Studies by the year they started
3 studies that test it; most in 2023 (1)
| Year | Studies |
|---|---|
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
Who runs them
Industry 3 · Other 0
ScinnoHub Pharmaceutical Co., Ltd. (3)
Often tested with
Tested in the same studies.
BT-14143 (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test BT-114143.
- Dec 2026Study on BT-114143 Reducing Perioperative Bleeding in Total Knee Arthroplasty(TKA)Phase 2 · ScinnoHub Pharmaceutical Co., Ltd.
Studies
Open first, then newest update. How each study uses BT-114143 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Study on BT-114143 Reducing Perioperative Bleeding in Total Knee Arthroplasty(TKA)RecruitingPhase 2ScinnoHub Pharmaceutical Co., Ltd.NCT07127042Written as Low-dose BT-114143
- Evaluation of Safety, Efficacy, and Pharmacokinetics of BT-114143 Injection in Patients With Abnormal Uterine BleedingRecruitingPhase 1ScinnoHub Pharmaceutical Co., Ltd.NCT07169214Written as BT-114143 Injection at low dose
- Evaluation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BT-114143 Injection in Healthy SubjectsCompletedPhase 1ScinnoHub Pharmaceutical Co., Ltd.NCT07169240Written as BT-114143